| Wenting Li,Shiying Yu. Research progress on immune checkpoint inhibitors in neoadjuvant therapy for gastric cancer. Oncol Transl Med, 2022, 8: 74-82. |
| Research progress on immune checkpoint inhibitors in neoadjuvant therapy for gastric cancer |
| Received:January 13, 2022 Revised:April 20, 2022 |
| View Full Text View/Add Comment Download reader |
| KeyWord:gastric cancer; immune checkpoint inhibitors (ICIs); neoadjuvant therapy |
| Author Name | Affiliation | E-mail | | Wenting Li | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | liwtpx@163.com | | Shiying Yu | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | syyu@tjh.tjmu.edu.cn |
|
| Hits: 2260 |
| Download times: 2639 |
| Abstract: |
| In recent years, immune checkpoint inhibitors (ICIs) have become an important treatment strategy for
advanced gastric cancer. Immunotherapy has gradually transitioned from a later-line to a first-line treatment
for advanced gastric cancer. Simultaneously, more and more researchers have begun to pay attention
to whether immunotherapy can be used for resectable gastric cancer. The current use of ICIs in the
neoadjuvant treatment of gastric cancer is still in its exploratory stage, with a number of clinical trials
currently underway. However, the available data show good application prospects. This article reviews
the research progress on ICIs in the neoadjuvant therapy for gastric cancer and evokes some unresolved
problems. |
| Close |
|
|
|